NVUS News and Press, Novus Therapeutics Inc. From 07/22/19

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced th...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that data from OP0201 study C-002 will be presented during the 20th International Symposium on Recent Adv...

Novus Therapeutics (NASDAQ: NVUS ) has slipped 7.8% in Friday postmarket action after a shareholder filing to offer just over 7.07M shares. More news on: Novus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers:  Novan (NASDAQ: NOVN ) +27% . Sea Limited (NYSE: SE ) +23% . Allied Healthcare Products (NASDAQ: AHPI ) +17% . Westwater Resources (NASDAQ: WWR ) +12% . Novus Therapeutics (NASDAQ: NVUS ) +12% . Spherix Incorporated (NASDAQ: SPEX ) +11% . CSW Industrials (NASDAQ: CSWI )...

Novus Therapeutics (NASDAQ: NVUS ): Q1 GAAP EPS of -$0.52 misses by $0.04 . More news on: Novus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended March 31, 2019. Operational Highlights Announced resu...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced registered direct offering of 3,449,112 shares of its common stoc...

Thinly traded nano cap Novus Therapeutics ( NVUS -16.3% ) is down on almost a 5x surge in volume, albeit on turnover of only 160K shares, in reaction to its at-the-market direct offering of 3,449,112 common shares at $3.095 per share to institutional and accredited investors. More news...

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agreements with several institutional and accredited investors for th...